| Project/Area Number |
20590954
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Kidney internal medicine
|
|---|
| Research Institution | Kyoto University |
|---|
Principal Investigator |
YANAGITA Motoko Kyoto University, 次世代研究者育成センター, 准教授 (70378769)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
SAKURAI Takeshi 金沢大学, 医学研究科, 教授 (60251055)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2009: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
Fiscal Year 2008: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Keywords | 慢性腎臓病 / 糸球体 / 尿細管 / 修復 / 腎臓病 / BMP / アルポート症候群 / 分化 / 再生 |
|---|
| Research Abstract |
Dialysis dependency is one of the leading causes of morbidity and mortality in the world, and once end-stage renal disease develops, it cannot be reversed by currently available therapy. Although the administration of large dose of bone morphogenetic protein7 (BMP7) has been shown to repair established renal injuries and improves renal function, pathophysiological role of endogenous BMP7 and regulatory mechanism of its activities remain elusive. Here we show that uterine sensitization-associated gene-1 (USAG-1), novel BMP antagonist abundantly expressed in the kidney, is the central negative regulator of BMP function in the kidney, and that inhibition of USAG-1 will be promising therapeutic trial for kidney diseases.
|
